Patient-reported outcomes from the EV-302/KEYNOTE-A39 trial

Dr Shilpa Gupta, a medical oncologist at the Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, presented patient-reported outcomes (PRO) from the EV-302/KEYNOTE-A39 trial. She emphasised the importance of these outcomes for patients throughout their treatment period. PRO assessments included the EORTC QLQ-C30 and the BPI-SF, which were completed at baseline, weekly for 12 weeks, and then every 3 weeks through survival follow-up, including the post-progression period.

The most significant benefit was observed in patients with moderate to severe pain at baseline who were treated with enfortumab vedotin plus pembrolizumab (EV+P). These patients experienced a meaningful improvement from baseline in BPI worst pain scores from week 3 through week 26. Patients treated with EV+P showed improved survival compared with those receiving platinum-based chemotherapy (PBC), without detriment to quality of life and functioning. However, compliance, particularly after progression, was lower than expected, especially in the PBC arm, which may have impacted the results.